NCT06931691Toboroz

A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China

A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan on Disease Management, Treatment-Related Outcomes and Healthcare Resource Utilization for Adult Patients With Paroxysmal Nocturnal Hemoglobinuria in China

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. jún. 1.

Következő lépések

Rövid összefoglaló (regiszter, angolul)

The implementation of new standards for the management of PNH and the use of iptacopan in patients with PNH are expected to change the treatment landscape and improve the overall prognosis of patients. Based on these backgrounds, we plan to conduct a real-world study of iptacopan to further evaluate its impact on treatment-related outcomes, disease management, and healthcare resource utilization in Chinese patients with PNH.

Állapot (regiszter): Toboroz
Vizsgálattípus: Megfigyeléses
Résztvevők száma: 80 (tervezett)
Első benyújtás: 2025. márc. 14.
Kezdés: 2025. jún. 10.
Elsődleges befejezés: 2027. ápr. 21.
Fő szponzor: Novartis Pharmaceuticals
NCT-szám: NCT06931691

Mit vállalsz

Vizsgálat típusa: Megfigyeléses
Tervezett résztvevők: 80
2025. jún. 10. és az elsődleges befejezés (2027. ápr. 21.) között
10 helyszín, 1 országban
Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Kiket keres a vizsgálat

Patient who meets all the following criteria can be included in this study:
Age ≥ 18 years at the time of signing the ICF;
Patient with a documented diagnosis of PNH;
Patient who has never received complement inhibitor therapy;
Patient who is initiating iptacopan therapy; Patient who is initiating iptacopan therapy must start the first dose within 60 days of signing the ICF;
Documented vaccination against Neisseria meningitidis and Streptococcus pneumoniae and the date of vaccination must be at least 2 weeks prior to the date of iptacopan initiation; If an urgent prescription for Iptacopan is needed, it is recommended that the antibiotic be used continuously according to the drug label until 14 days after the vaccination is completed, and that the vaccination be completed as soon as possible.
Patient who has signed the ICF.
- For Cohort 2,
- Patient who meets all the following criteria can be included in this study:
Age ≥ 18 years at the time of signing the ICF;
Patient with a documented diagnosis of PNH; Patients who have been receiving stable treatment with C5 complement inhibitors for at least three months prior to enrollment;
Patient who is initiating iptacopan therapy; Patient who is initiating iptacopan therapy must start the first dose within 60 days of signing the ICF;
Documented vaccination against Neisseria meningitidis and Streptococcus pneumoniae and the date of vaccination must be at least 2 weeks prior to the date of iptacopan initiation;
If an urgent prescription for Iptacopan is needed, it is recommended that the antibiotic be used continuously according to the drug label until 14 days after the vaccination is completed, and that the vaccination be completed as soon as possible.
Patient who has signed the ICF. Exclusion criteria
- For Cohort 1 and Cohort 2, patients who meet any of the following criteria will meet the exclusion criteria for this study:
Participating in an interventional PNH clinical study;
Have an active systemic bacterial, viral (incl. COVID-19) or fungal infection within 14 days prior to first dose;
Documented with a history of recurrent invasive infections, e.g. active systemic bacterial, viral or fungal infection within 14 days prior to first dose;
Documented with a history of HIV infection;
Women who are pregnant or breastfeeding or intending to conceive during the study period;
Existence of bone marrow failure (reticulocytes < 100 × 109/L, platelets < 30 × 109/L, and neutrophils < 0.5 × 109/L) determined by the investigator;
Other conditions that are not suitable for participating in the study, in the judgment of the investigator.

Életkor a regiszterben: 18 év – 80 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (10)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

Helyszín	Város	Ország	Helyszín állapota
-	Changchun	Kína	Toboroz
-	Guangzhou	Kína	Toboroz
-	Hefei	Kína	Toboroz
-	Jinan	Kína	Toboroz
-	Nanchang	Kína	Toboroz
-	Nantong	Kína	Toboroz
-	Shijiazhuang	Kína	Toboroz
-	Tianjin	Kína	Toboroz
-	Wuhan	Kína	Toboroz
-	Zhengzhou	Kína	Toboroz

Te vagy a koordinátor? Erősítsd meg az adatokat

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.